IL1A and metastatic colorectal cancer: TASKIN is the first early-phase clinical trial testing the hypothesis of tolerance and efficacy of the association between trifluridine/tipiracil + bevacizumab and anti-IL-1α mAb immunotherapy for multi-treatment metastatic colorectal cancer (mCRC).